Acetazolamide (Diamox) Brain Perfusion & Cerebrovascular Reserve⁹⁹ᵐTc-HMPAO / ECD

Quick Answer

Acetazolamide (Diamox) brain-perfusion SPECT measures cerebrovascular reserve (CVR) — the brain's capacity to increase blood flow when challenged. A baseline perfusion study (Tc-99m-HMPAO or ECD) is compared with a post-acetazolamide (vasodilator-challenge) study: normal vasculature dilates and augments flow, while territory whose arterioles are already maximally dilated to maintain resting flow (exhausted reserve) cannot augment — appearing as a relative defect only after the challenge. This identifies hemodynamically significant carotid occlusion, moyamoya, and candidates for revascularization (e.g., EC-IC bypass) — disease that a resting scan can miss.

Background & Physiology

Cerebral autoregulation keeps resting perfusion constant across a range of perfusion pressures by dilating arterioles as pressure falls. When a proximal stenosis/occlusion drops perfusion pressure, distal arterioles progressively dilate to preserve resting flow — consuming the reserve. Acetazolamide, a carbonic-anhydrase inhibitor, raises tissue CO₂/H⁺ and is a potent cerebral vasodilator: it dilates normal vessels ~30–60%, but territory already maximally dilated (reserve exhausted) cannot respond, so its relative perfusion falls on the challenge study (a "steal"-like redistribution toward normal territory).

Clinical Indications

• Hemodynamic significance of carotid/intracranial occlusive disease — deciding whether a stenosis/occlusion is flow-limiting.
• Moyamoya disease — pre- and post-operative reserve assessment.
• Selection for revascularization (carotid endarterectomy/stenting, EC-IC bypass) and monitoring after.
• Chronic hypoperfusion / borderzone evaluation and vasospasm-risk contexts.

Technique

• Baseline perfusion SPECT (HMPAO/ECD), then a separate-day or same-day split-dose study with acetazolamide (~1 g IV) given ~15–20 min before the challenge-phase injection.
• Compare baseline vs post-acetazolamide regional perfusion (visual and semiquantitative/ROI).
• Screen for contraindications: sulfonamide allergy, significant renal impairment, and caution near recent stroke.

Interpretation

A normal resting scan that fails to augment is the key finding — it reveals hemodynamically compromised but not-yet-infarcted tissue that resting imaging alone would call normal.

Reporting Checklist

• State baseline vs challenge findings by territory and the augmentation response (normal / blunted / paradoxical decrease).
• Classify cerebrovascular reserve (normal vs exhausted) and correlate with the vascular lesion.
• Note acetazolamide dose/timing and any contraindication screening.

Common Pitfalls

• Reading only the resting study (misses exhausted reserve — the whole point of the challenge).
• Sulfa allergy / renal impairment contraindications not screened.
• Global poor augmentation from technical/physiologic factors (caffeine, medications) mimicking bilateral disease.
• Confusing the challenge-induced relative defect with a fixed perfusion defect.

Board Pearls

Acetazolamide (Diamox) is a carbonic-anhydrase-inhibitor cerebral vasodilator; comparing baseline vs post-acetazolamide perfusion SPECT measures cerebrovascular reserve. Normal vessels augment flow; territory with exhausted reserve (arterioles already maximally dilated to keep resting flow) cannot augment and drops relatively — unmasking hemodynamically significant carotid occlusion/moyamoya that a resting scan misses.

The decisive pattern is a normal resting scan that fails to augment after challenge — hemodynamically compromised, not-yet-infarcted tissue. This identifies patients who may benefit from revascularization (EC-IC bypass, endarterectomy/stenting).

Contraindications: sulfonamide allergy and significant renal impairment; caution in acute stroke. A paradoxical "steal" (relative decrease in the compromised territory as normal territory dilates) reflects redistribution, not new ischemia. Semiquantitative ROI comparison improves reproducibility; global blunting can be technical/physiologic (screen caffeine/meds).

Related Pages

• Tracer: brain perfusion agents (HMPAO/ECD); related: brain FDG/dementia, brain death perfusion.

Figure / Diagram Suggestions

• A reserve-vs-pressure autoregulation curve (arteriolar dilation consuming reserve).
• A baseline-normal / challenge-defect teaching pair (exhausted reserve).

Self-Check